In line with Dr. Judy Davie’s webinar on Patient Derived Xenografts (PDXs), you might also want to read the following article published in the March 2014 issue of Cancer: Patient-Derived Xenografts for Individualized Care in Advanced Sarcoma. PMID24705963-PDX-for-RMS
Background: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method (“TumorGrafts”).
Authors: Justin Stebbing, MA, FRCP, FRCPath, PhD; Keren Paz, PhD; Gary K. Schwartz, MD; Leonard H.Wexler, MD; Robert Maki, MD, PhD; Raphael E. Pollock, MD, PhD; Ronnie Morris, MD; Richard Cohen, MD; Arjun Shankar, MD; Glen Blackman, MBBS; Victoria Harding, MD; David Vasquez, MD; Jonathan Krell, MD,